Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 8 full-time employees. The company has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for SEELQ. Our analysts highlight strong fundamentals and favorable market sentiment, positioning SEELQ for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: SEELQ is a Strong Buy candidate.
SEELQ stock price ended at $0 on 月曜日, after rising NaN%
On the latest trading day Jun 01, 2026, the stock price of SEELQ rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 559 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 445 shares were traded, amounting to a market value of approximately --.